2,4-diamino-5-methyl-5-deaza-6-bromomethylpteridine | 101348-32-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 2,4-diamino-5-methyl-5-deaza-6-bromomethylpteridine
• 英文别名: 2,4-diamino-5-methyl-6-(bromomethyl)pyrido<2,3-d>pyrimidine；6-(bromomethyl)-2,4-diamino-5-methylpyrido<2,3-d>pyrimidine；2,4-diamino-6-(bromomethyl)-5-methylpyrido<2,3-d>pyrimidine；6-(bromomethyl)-2,4-diamino-5-methyl-5-deazapteridine；2,4-diamino-6-(bromomethyl)-5-methyl-5-deazapteridine；Pyrido[2,3-d]pyrimidine-2,4-diamine, 6-(bromomethyl)-5-methyl-；6-(bromomethyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
• CAS: 101348-32-7
• 化学式: C₉H₁₀BrN₅
• 分子量: 268.116
• InChiKey: WDKGMVOPUGQGQY-UHFFFAOYSA-N

物化性质

• 沸点：
  542.9±60.0 °C(Predicted)
• 密度：
  1.746±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  90.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,4-diamino-5-methyl-5-deaza-6-bromomethylpteridine 在 sodium hydroxide 作用下， 以 甲醇 、 N,N-二甲基乙酰胺 为溶剂， 反应 144.0h， 生成 N-pyrimidin-6-yl)methyl>amino>benzoyl>-L-glutamic acid
  参考文献：
  名称：

  氨基蝶呤和叶酸的5-脱氮类似物的合成和生物活性。

  摘要：

  N- [p-[[（（2,4-二氨基吡啶并[2,3-d]嘧啶-6-基）甲基]氨基]苯甲酰基] -L-谷氨酸（1a，5-deazaaminopterin）和5-甲基类似物（1b）分别由5-氰尿嘧啶（4a）和5-氰基-6-甲基尿嘧啶（4b）分14步合成，通过利用新型嘧啶进行吡啶并[2,3-d]嘧啶环转化反应。用氯甲基甲基醚将5-氰尿嘧啶4处理成1，3-双（甲氧基甲基）尿嘧啶（5，将其在NaOEt / EtOH中用丙二腈处理，得到吡啶并[2,3-d]嘧啶6。在浓盐酸中6生成高产率的7-氯衍生物8，还原8后，在Ac2O存在下还原7-未取代的产物9，然后将6-（乙酰氨基甲基）吡啶并嘧啶10转化为6 -乙酰氧基甲基衍生物12通过亚硝化。从12除去N-甲氧基甲基后，将6-（乙酰氧基甲基）吡啶并[2,3-d]嘧啶-2,4（1H，3H）-二酮14转化为2,4-二氨基-6-（通过甲硅烷基化-胺化步骤得到羟甲基）吡啶并[2

  DOI：

  10.1021/jm00155a021
• 作为产物：
  描述：

  2-氨基-6-氯-3,5-二氰基-4-甲基吡啶 在 palladium-barium carbonate 、 镍 sodium tetrahydroborate 、 甲酸 、 乙醇 、 氢气 、 sodium 、 triphenylphosphine dibromide 1:1 addition complex 作用下， 以 甲醇 、 N,N-二甲基乙酰胺 、 N,N-二甲基甲酰胺 为溶剂， 20.0~80.0 ℃ 、344.73 kPa 条件下， 反应 23.0h， 生成 2,4-diamino-5-methyl-5-deaza-6-bromomethylpteridine
  参考文献：
  名称：

  氨基蝶呤，甲氨蝶呤，叶酸和N10-甲基叶酸的5-甲基-5-脱氮类似物的合成和抗叶酸活性。

  摘要：

  有证据表明，经典叶酸抗代谢物的5位和10位修饰导致化合物与正常增生组织相比在肿瘤中具有有利的差异膜转运，这促使人们对5-烷基-5-脱氮类似物进行了研究。将其已知的6-氯前体进行氢解制得的2-氨基-4-甲基-3,5-吡啶二甲腈用胍处理，得到2,4-二氨基-5-甲基吡啶[2,3-d]嘧啶-6 -甲腈，其通过相应的醛和羟甲基化合物转化为6-（溴甲基）-2,4-二氨基-5-甲基吡啶并[2,3-d]嘧啶。腈8与N-（4-氨基-苯甲酰基）-L-谷氨酸二乙酯的还原缩合，然后酯水解，得到5-甲基-5-脱氮杂min蝶呤。用甲醛和Na（CN）BH3处理12，得到5-甲基-5-脱氮甲氨蝶呤，它也由15和N-[（4-甲基氨基）苯甲酰基] -L-谷氨酸二甲酯制备，然后酯水解。5-甲基-10-乙基-5-脱氮杂氨基蝶呤类似地由15制备。对5-甲基-5-脱氮杂类似物与先前报道的5-脱氮杂氨基蝶呤和5-脱氮氨甲蝶呤的生物学

  DOI：

  10.1021/jm00156a029

文献信息

• Synthesis and Biological Evaluation of Nonclassical 2,4-Diamino-5-methylpyrido[2,3-<i>d</i>]pyrimidines with Novel Side Chain Substituents as Potential Inhibitors of Dihydrofolate Reductases
  作者：Aleem Gangjee、Anil Vasudevan、Sherry F. Queener

  DOI：10.1021/jm960734f

  日期：1997.2.1

  Nine novel 2,4-diamino-5-methyl-6-substituted-pyrido[2,3-d]pyrimidines, 2-10, were synthesized as potential inhibitors of Pneumocystis carinii dihydrofolate reductase (pcDHFR) and Toxoplasma gondii dihydrofolate reductase (tgDHFR). Compounds 2-5 were designed as conformationally restricted analogues of trimetrexate (TMQ), in which rotation around tau 3 was constrained by incorporation of the side chain

  合成了9种2,4-二氨基-5-甲基-6-取代的吡啶并[2,3-d]嘧啶2-10作为卡氏肺孢子虫二氢叶酸还原酶（pcDHFR）和弓形体弓形虫二氢叶酸还原酶（tgDHFR）的潜在抑制剂）。化合物2-5被设计为曲美曲塞（TMQ）的构象受限类似物，其中围绕tau 3的旋转通过结合侧链氮作为二氢吲哚或吲哚环的一部分而受到限制。在侧链氮和苯环之间具有额外原子的类似物6，其氮为四氢异喹啉环的一部分。类似物7-9是表柔伯霉素（Ro 11-8958）类似物，并且与吡咯伯胺类似，在苯基环上含有吡咯环作为侧链取代的一部分。设计这些类似物以研究吡咯取代在2,4-二氨基-5-甲基-6-（苯胺基甲基）吡啶并[2,3-d]嘧啶的苯环上的作用。分子模型表明，在侧链苯环邻位的吡咯取代基最有可能与pcDHFR相互作用，其方式与表必隆的吡咯部分相似。合成类似物10，其中苯环取代了甲氧基，以确定苯环对选择性，亲脂性和细胞渗透性的
• Analogues of Methotrexate in Rheumatoid Arthritis. 2. Effects of 5-Deazaaminopterin, 5,10-Dideazaaminopterin, and Analogues on Type II Collagen-Induced Arthritis in Mice
  作者：James R. Piper、Joseph I. DeGraw、William T. Colwell、Cheryl A. Johnson、R. Lane Smith、William R. Waud、Francis M. Sirotnak

  DOI：10.1021/jm950553y

  日期：1997.1.1

  aminopterin analogues were evaluated for antiarthritic activity in the mouse type II collagen model. New compounds in the 5-deaza series were prepared by alkylation of an appropriate N-substituted (4-aminobenzoyl)-L-glutamic acid dialkyl ester or N-(5-amino-2-thenoyl)-L-glutamate diester with a 2,4-diamino-5-alkyl-6-(bromomethyl)-5-deazapteridine. The resultant 5-deazaaminopterin diesters were saponified

  在小鼠II型胶原蛋白模型中评估了衍生自5-deaza-和5,10-dideazaaminopterin系列的氨基蝶呤类似物的26种化合物的抗关节炎活性。通过将合适的N-取代的（4-氨基苯甲酰基）-L-谷氨酸二烷基酯或N-（5-氨基-2-thenoyl）-L-谷氨酸二酯烷基化来制备5-deaza系列的新化合物，4-二氨基-5-烷基-6-（溴甲基）-5-脱氮庚啶。将所得的5-脱氮杂min蝶呤二酯皂化以提供目标5-脱氮杂合物类似物。通过适当的4-羧基苯基乙酸，（5-羧基-2-噻吩基）乙酸或（5-羧基-2-吡啶基）乙酸二甲基酯的碳负​​离子的类似烷基化反应合成5,10-二氮杂氨基蝶呤。2,4-二氨基-4-脱氧-10-羧基-5的二酯 将如此获得的10-二氮杂叠氮酸类型皂化，然后通过在Me 2 SO溶液中加热而容易地脱羧，以提供2，4-二氨基-5，10-二氮杂叠氮酸类型的中间体。肽与L-谷氨酸二乙酯偶
• Antimycobacterial Activities of 2,4-Diamino-5-Deazapteridine Derivatives and Effects on Mycobacterial Dihydrofolate Reductase
  作者：William J. Suling、Lainne E. Seitz、Vibha Pathak、Louise Westbrook、Esther W. Barrow、Sabrina Zywno-van-Ginkel、Robert C. Reynolds、J. Robert Piper、William W. Barrow

  DOI：10.1128/aac.44.10.2784-2793.2000

  日期：2000.10

  were active against MAC NJ168 at concentrations of < or =13 microg/ml. Depending on the MAC strain used, 81 to 87% had MICs of < or =1.3 microg/ml. Twenty-one derivatives were >100-fold more active against MAC rDHFR than against human rDHFR. In general, selectivity was dependent on the composition of the two-atom bridge at position 6 and the attached aryl group with substitutions at the 2' and 5' positions

  开发用于鸟分枝杆菌复合体 (MAC) 感染的新抗分枝杆菌药物对于同时感染人类免疫缺陷病毒的人来说尤其重要。本研究的目的是评估 2, 4-diamino-5-methyl-5-deazapteridines (DMDPs) 对 MAC 的体外活性，并评估它们对 MAC 二氢叶酸还原酶重组酶 (rDHFR) 的活性。最初评估了 77 种 DMDP 衍生物对一到三株 MAC（NJ168、NJ211 和/或 NJ3404）的体外活性。用 10 倍稀释的药物和比色法（Alamar Blue）微量稀释肉汤测定法测定 MIC。还确定了 MAC rDHFR 50% 抑制浓度与人 rDHFR 的抑制浓度。蝶啶部分第 5 位的取代基包括 -CH(3)、-CH(2)CH(3) 和 -CH(2)OCH(3) 基团。此外，不同的取代和未取代的芳基通过 -CH(2)NH、-CH(2)N(CH(3))、-CH(2)CH(2)
• [EN] DEAZAAMINOPTERINS FOR TREATMENT OF INFLAMMATION<br/>[FR] DESAZAAMINOPTERINES POUR LE TRAITEMENT DES INFLAMMATIONS
  申请人：SRI INTERNATIONAL

  公开号：WO1993022312A1

  公开（公告）日：1993-11-11

  (EN) 5-Alkyl, 5-alkenyl, 5-alkynyl, and heteroaroyl-5-deazaaminopterins and 5,10-dideazaaminopterins are provided, as well as a method and composition employing such compounds for the treatment of inflammatory disease, such as rheumatoid arthritis.(FR) L'invention concerne des 5-alkyl, 5-alcényl, 5-alkynyl, et hétéroaroyl-5-désazaaminoptérines et des 5,10-didésazaaminoptérines ainsi qu'un procédé et une composition utilisant ces composés pour le traitement de maladies inflammatoires telles que la polyarthrite rhumatoïde.

  (EN) 5-烷基、5-烯基、5-炔基以及杂环芳香基-5-去氨基氨基(TRUE)化合物，以及5,10-二去氨基氨基(TRUE)化合物和采用这些化合物来治疗类风湿性关节炎的方法及成分。 (FR) 该发明涉及5-烷基、5-烯基、5-炔基以及杂环芳香基-5-去氨基氨基TRUE化合物、5,10-二去氨基氨基TRUE化合物，以及采用这些化合物来治疗类风湿性关节炎的方法、成分。
• Lipophilic Antifolates as Agents against Opportunistic Infections. 1. Agents Superior to Trimetrexate and Piritrexim against <i>Toxoplasma gondii</i> and <i>Pneumocystis carinii</i> in <i>in Vitro</i> Evaluations
  作者：James R. Piper、Cheryl A. Johnson、Charles A. Krauth、Ronald L. Carter、Carla A. Hosmer、Sherry F. Queener、Susan E. Borotz、Elmer R. Pfefferkorn

  DOI：10.1021/jm950760y

  日期：1996.3.15

  2,4-Diaminopteridines (21 compounds) and 2,4-diamino-5-methyl-5-deazapteridines (34 compounds) along with three 2,4-diamino-5-unsubstituted-5-dieazapteridines and four 2,4-diaminoquinazolines, each with an aryl group attached to the 6-position of the heterocyclic moiety through a two-atom bridge (either CH2NH, CH2N(CH3), CH2S, or CH2CH2), were synthesized and evaluated as inhibitors of the growth of Toxoplasma gondii in culture and as inhibitors of dihydrofolate reductase enzymes from T. gondii, Pneumocystis carinii, and rat liver. Exceptionally high levels of combined potency and selectivity as growth inhibitors of T. gondii and as inhibitors of the microbial enzymes relative to the mammalian enzyme were found among the 5-methyl-5-deazapteridines but not for the other heterocyclic types. Thirty of the 34 5-methyl-5-deaza compounds gave growth inhibition IC50 values lower than that of pyrimethamine (0.4 mu M) with 14 compounds below 0.1 mu M, values that compare favorably with those for piritrexim and trimetrexate (both near 0.02 mu M). As inhibitors of T. gondii DHFR, all but three of the 34 5-methyl-5-deaza compounds gave IC50 values in the order of magnitude with those of piritrexim (0.017 mu M) and trimetrexate (0.010 mu M), and 17 compounds of this group gave IC50 values versus P. carinii DHFR similarly comparable with those of piritrexim (0.031 mu M) and trimetrexate (0.042 mu M). Thirteen of these congeners gave both T. gondii growth inhibition and DHFR inhibition IC50 values of 0.10 mu M or less, thus indicating facile penetration of the cell membrane. Eleven of these inhibitors of both T. gondii growth and DHFR have selectivity ratios (IC50 rat liver divided by IC50 T gondii) of 5 or greater for the parasite DHFR. The highest selectivity ratio of nearly 100 belongs to the 5-methyl-5-deaza compound whose B-substituent is CH2CH2C6H3(OCH3)(2)-2,5. This compound is over 10(3)-fold more selective for T. gondii DHFR than bridge homologue piritrexim (selectivity ratio 0.088), a compound now in clinical trials. The candidate with CH2NHC6H3(CH3)(2)-2,5 in the 6-position gave the highest P. carinii DHFR selectivity ratio of 4.0, which is about 60-fold more selective than trimetrexate (0.071) and 80-fold more selective than piritrexim (0.048) toward this enzyme. The 10 best compounds with respect to potency and selectivity includes six compounds bearing 2,5-disubstituted phenyl groups in the side chain (with little, if any, difference in effects of methyl, methoxy, or ethoxy), two side chains bearing 1-naphthyl groups, and two with 5,6,7,8-tetrahydro-1-naphthyl groups. Bridge groups represented in the 10 choice compounds are CH2NH, CH2N(CH3), CH2CH2, and CH2S. The high levels of both potency and selectivity among these agents suggest that in vivo studies now underway may lead to agents that could replace trimetrexate and piritrexim in treatment of toxoplasmosis and P. carinii pneumonia.